Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 07/30/18

Fernanda I. Arnaldez, MD

Fernanda Arnaldez


Fernanda Arnaldez, MD, joined the Investigational Drug Branch, CTEP, in 2017 as a Physician in the Investigational Therapeutics 1 Section where she develops clinical trials within the CTEP portfolio. In addition, she is the Scientific Officer for the Experimental Therapeutics Clinical Trials Network (ETCTN) and the Early Drug Development Opportunity Program (EDDOP) Coordinator.

Her background includes oncology research in government, industry and academia. She graduated with high honors from University of Buenos Aires School of Medicine in Buenos Aires, Argentina. She completed residency training at Ricardo Gutierrez Children's Hospital in Buenos Aires, where she served as Chief Pediatric Resident and ad-honorem attending physician. She came to the US in 2005, where she pursued further training at the University of Pittsburgh Medical Center.

Dr. Arnaldez joined the Johns Hopkins University / NCI Pediatric Oncology Training Program in 2008 and served there as Chief Clinical Fellow in 2011; at the same time, she was pursuing post-doctoral training in the Molecular Oncology Section led by Dr. Lee Helman. She specialized in Solid Tumor Oncology and became Assistant Clinical Investigator and a Sarcoma Team Member at the Center for Cancer Research (CCR) in 2012. In her laboratory, she led multidisciplinary preclinical drug discovery efforts in pediatric rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma. Dr. Arnaldez then joined Novartis Pharmaceuticals Corporation, where she was a Global Clinical Leader in Oncology.

She returned to CCR as an Associate Research Physician in 2016, where she continues to lead, concomitantly with her IDB position, multidisciplinary efforts to develop innovative therapeutic modalities for patients with rare malignancies and pediatric solid tumors. She is also the director of the Wild-Type Gastrointestinal Stromal Tumor clinic at NCI and a key member of the rare tumors program.

Dr. Arnaldez also earned a type of MBA tailored for Pharma in 2015 from Rutgers University. She is a member of several pediatric medical societies, as well as ASCO and AACR. She is the recipient of numerous awards, including the Brigid Leventhal Special Merit Award (ASCO), the Conquer Cancer Foundation Young Investigator Award, and the American Society of Pediatric Hematology-Oncology Young Investigator Award.

Contact Information:
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
Phone: 240-276-6565
Fax: 240-276-7894

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in January 2014 after serving part time since August 2012. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. He completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…